Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 784

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 784
---
 Convertible Note PIPE Subscribers
” and together with the Equity PIPE Subscribers, the “

#### PIPE Subscribers
” and together with the Sponsor, Cantor, the Liminatus Members and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 6.2 of this Agreement, a “

#### Holder
” and collectively the “

#### Holders
”).

### RECITALS

### WHEREAS
, the SPAC and certain former holders of the SPAC entered into that certain Registration Rights Agreement dated March 4, 2021 (the “

#### Original Agreement
”);

### WHEREAS
, Sponsor succeeded to the rights of the former holders under the Original Agreement;

### WHEREAS
, ParentCo, Sponsor, Liminatus Pharma LLC, a Delaware corporation (“

#### Liminatus
”), Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ParentCo (“

#### Liminatus Merger Sub
”), and SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ParentCo (“

#### SPAC Merger Sub
”) entered into a Business Combination Agreement as of November 30, 2022 (as amended, modified, supplemented or waived from time to time, the “

#### Transaction Agreement
” and the transactions contemplated by the Transaction Agreement to be completed on and prior to the closing date thereof, collectively, the “

### Business Combination
”), pursuant to which, among other things, in the manner, and on the terms and subject to the conditions and exclusions set forth therein, effective as of the closing of the Business Combination, (a) Liminatus Merger Sub will merge with and into Liminatus, with Liminatus surviving as a direct wholly-owned subsidiary of ParentCo (the “

#### Company Merger
”), and (b) simultaneously with the Company Merger, SPAC Merger Sub will merge with and into IRIS, with IRIS surving as a direct wholly-owned subsidiary of ParentCo (the “

#### SPAC Merger
” and, together with the Company Merger, the “

#### Mergers
”).

### WHEREAS
, pursuant to the Mergers, the Sponsor and Liminatus Members were issued common stock, par value $0.0001 of ParentCo (“

#### Common Stock
”) and may be issued shares of Common Stock in the future pursuant to the terms of the Transaction Agreement;

###